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Objective: To investigate whether clinical criteria could differentiate between women with vulvovaginitis who
were culture positive or negative for vaginal Candida species.
Methods: Vulvovaginal specimens were obtained from 501 women with a vaginal discharge and/or pruritis.
Clinical information and wet mount microscopy findings were obtained. All specimens were sent to a central
laboratory for species identification.
Results: A positive culture for Candida species was obtained from 364 (72.7%) of the specimens. C. albicans was
identified in 86.4% of the positive cultures,followed by C. glabrata in 4.5%, C. parapsilosis in 3.9%, C. tropicalis in
2.7%andotherCandida speciesin1.4%.WomenwithapositiveCandidaculturehad anincreasedutilization oforal
contraceptives (26.1% vs. 16.8%, p = 0.02) and antibiotics (8.2% vs. 0.7%, p = 0.001), and were more likely to
be pregnant (9.1% vs. 3.6%, p = 0.04) than the culture-negative women. Dyspareunia was more frequent in
women without Candida (38.0% vs. 28.3%, p = 0.03) while vaginal erythema (p = 0.01) was more common in
women with a positive Candida culture.
Conclusions: Although quantitative differences were observed, the presence of vaginal Candida vulvovaginitis
cannot be definitively identified by clinical criteria.
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Itisdifficulttoobtainaccurateinformationregard-
ing the prevalence and incidence of vulvovaginitis
associated with a Candida species infection.
Although up to 75% of women will acknowledge
havinghad avaginalCandidainfectionduringtheir
lifetime1, this diagnosis is suspect. The skyrocket-
ing sales of over-the-counter medications for
Candida vaginitis, at a rate many times that of the
number of infected women, highlights the preva-
lent overdiagnosis of this disorder. Many women,
and unfortunately also many clinicians, label any
vaginal discharge, itching, pain or burning as a
‘yeast’ infection. In three studies, more than half of
thewomen with a supposedvaginal yeast infection
were misdiagnosed2–4.
Conversely, in many women a true vaginal
Candida infection may remain unrecognized.
Detectionof a vaginal Candida infection bymicro-
scopic examination of a vaginal specimen diluted
in potassium hydroxide is relatively insensitive,
especially fornon-albicansspecies3,5.False-positive
microscopicexaminationsarealso possible5andare
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Clinical Study 221probably more common than generally suspected.
It is also possible to have Candida vulvovaginitis
witha false-negative Candida culture.Atleast 3000
organisms/ml are necessary to obtain a positive
culture6.
In an attempt to more accurately characterize
symptomatic women with a positive Candida
species vaginal culture, and to differentiate them
from women with vaginal symptoms due to other
causes,astudywasinitiatedinthreecitiesinBrazil.
MATERIALS AND METHODS
This study was approved by the Clinical and
Ethical Committee of Hospital das Clinicas, Uni-
versity ofSao Paulo,and informed written consent
was obtained from all subjects. The study popula-
tion consisted of 501 consecutive reproductiveage
women complaining of a vaginal discharge and/or
vulvovaginal pruritis, seen as private patientsin the
Brazilian cities of Sao Paulo, Rio Grande de Sul
and Salvador. Exclusion criteria included the use
of immunosuppressive medications, vaginal medi-
cations or oral antifungal agents within the last
30 days.
Clinicaland demographicdatawerecollectedat
each center by a single participating physician.
Signs and symptoms upon physical examination
were standardized as much as possible between the
different sites by providing common diagnostic
criteria for erythema, edema, discharge and
dysuria. Definitions were similar to those utilized
by Eckert and colleagues7.
Specimens were obtained by scraping the
vaginal walls with a cotton swab and immediately
transferring the contents to a glass slide. A drop of
saline was added and diagnosis of Candida was
based on the observed presence of mycelium
(branched hyphal elements) or blastospores (the
unicellular yeast form). A second specimen was
placed in transport medium and shipped to a
central clinical laboratory. Specimens were
cultured on Sabouraud agar containing chloram-
phenicol. Candida species were identified by
the automated Amphotericin B (ATB) express
method.
Comparisons between women with positive or
negative Candida cultures forquantitativevariables
were analyzed by the Student’s t-test for
independent samples. The c2 test was used to
compare qualitative variables between both
groups. Findings were considered significant at
p < 0.05.
RESULTS
Candida was detected by culture in 364 (72.7%) of
thesubjects.ThedistributionofindividualCandida
species can beseen inTable1. C. albicanswasiden-
tified in86.4% ofthepositivecultures,followedby
C. glabrata (4.5%), C. parapsilosis (3.9%) and
C. tropicalis (2.7%). A presumed identification of
Candida was made by microscopic examination
in 87.1% of women with a positive culture and in
5.1% of those with a negative culture. Trichomonas
vaginalis was present in 2.9% and 1.4% of women
with a negative and positive Candida culture,
respectively. Clue cells were observed in 16.8% of
women with a negative culture and in 9.1% of
womenwithapositiveCandida culture(p = 0.01).
For all analyses, the patients were divided into
two groups based on the presence or absence of a
positiveCandida culture.Demographicsofwomen
inbothgroupsareshownin Table2. A higherper-
centage of black women, but notof white women
or those of other races, were present in the
culture-negative group (16.8%) than in the
Candida culture-positive group (8.3%) (p = 0.01).
The relationship between predisposing factors
and a positive or negative Candida culture is
detailed in Table 3. Pregnancy (9.1% vs. 3.6%,
p = 0.04), oral contraceptive usage (26.1% vs.
16.8%, p = 0.02) and current antibiotic use (8.2%
vs. 0.7%, p = 0.001) were each associated with
detection of a positive Candida culture. Con-
versely, a positive HIV serology (7.3% vs. 3.3%,
Vulvovaginal symptoms and Candida infection Linhares et al.
222 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY
Candida species Percentage women positive
albicans
glabrata
parapsilosis
tropicalis
krusei
guilliermondii
famata
pulcherrima
susitanii
86.4
4.5
3.9
2.7
0.9
0.6
0.3
0.3
0.3
Table 1 Candida species identified by culturep = 0.05) and prior history of a sexually trans-
mitted disease (17.5% vs. 9.7%, p = 0.01) were
associated with a negative Candida culture. The
HIV-seropositive women were at the earliest
stages of their disease.
The relationship between patient-reported
signs and symptomsandCandida culturefindingsis
shown in Table 4. There was considerable overlap
between the two groupsin complaints of a vaginal
discharge, vulvar pruritis and burning, dysuria and
dyspareunia. Only dyspareunia was significantly
different between the two groups: 38.0% in
women with a negative culture vs. 28.3% in those
with a positive Candida culture (p = 0.03).
Clinicalfindingsinthepatientgroupsareshown
in Table 5. Although there was an overall high
degree of similarity between subjects regardless of
theirCandidaculturestatus,womenwithapositive
culture had a higher prevalence of vaginal
erythema (p = 0.01).
DISCUSSION
Although some quantitative differences in the
frequency of patient symptoms, clinical findings
and predisposing factors were identified between
groups of women who were culture-positive or
culture-negative for Candida species, none of
the evaluated criteria were pathognomonic for
Candida in the vagina. Similar findings have been
reported previously by others2,6–8. In a large study
of women attending a sexually transmitted disease
clinic, only 28% of 545 women with pruritis,
burning or a vaginal discharge were C. albicans-
culture positive7. Thus, in symptomatic women, a
positive wetmountorcultureforCandidais neces-
sary to assess whether this organism is present in
the vagina.
The findings in the present study of associations
betweenapositiveCandida cultureinsymptomatic
women and current oral contraceptive and anti-
biotic usage and pregnancy parallel earlier
reports9–11. We recognize that other studies have
Vulvovaginal symptoms and Candida infection Linhares et al.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 223
Candida
(n = 364)
No Candida
(n = 137)
Race
White
Black
Oriental
Other
Age (years)
Sexually active
> 1 Sexual partner
79.0%
8.3%
5.0%
7.7%
32.2 (10.1)†
93.1%
7.5%
73.7%
16.8%*
1.5%
8.0%
33.8 (10.8)†
84.7%
3.1%
*p = 0.01 vs. black women with Candida;
†standard deviation
Table 2 Demographics of women with vulvovaginitis
and a positive or negative culture for Candida
Candida No Candida
Diabetes
Pregnancy
Oral contraception
IUD usage
Corticosteroid usage
Antibiotic usage
HIV seropositive
Prior STD
2.8%
9.1%*
26.1%**
6.6%
2.2%
8.2%***
3.3%
9.7%
4.4%.
3.6%.
16.8% .
11.0% .
2.2%.
0.7%.
7.3%†
17.5%††
*p = 0.04, **p = 0.02, ***p = 0.001 vs. women without Candida;
†p = 0.05,
††p = 0.01 vs. women with Candida
Table 3 Predisposing factors associated with Candida
species culture-positive and -negative vulvovaginitis
Candida No Candida
Vulvar pruritis
Vulvar burning
Vaginal discharge
Dyspareunia
Dysuria
>1 previous episode
Length of symptoms (days)
83.2%
61.8%
85.7%
28.3%
19.8%
44.5%
18.6 ± 8.6
82.5%
66.4%
87.6%
38.0%*
21.9%
53.3%
15.0 ± 12.0
*p = 0.03 vs. women with Candida
Table 4 Signs and symptoms of women with vulvo-
vaginitis positive and negative for Candida by culture
Candida No Candida
Vulvar edema
Vulvar erythema
Vaginal fissures
Vaginal erythema
Leukorrhea
Excoriation
Cervical ectopy
Vesicles
Pustules
10.7%
16.5%
18.4%
86.8%*
84.9%
9.9%
11.5%
2.2%
2.2%
9.5%
16.3%
16.1%
59.2%
88.6%
8.8%
14.6%
2.2%
2.2%
*p = 0.01 vs. women without Candida
Table 5 Clinical findings in women with vulvovaginitis
and positive or negative for Candida by culturereported that women using oral contraceptives
containing estrogen levels of 35 mg or less did not
have an increased rate of candida vulvo-
vaginitis7,11,12. Thisdoesnotseem to betrue, how-
ever, forourstudypopulation.Theoralcontracep-
tives used by the patients examined contained
estrogen levels below 35 mg.
The etiology of the vaginal symptoms in the
majority of our 137 Candida culture-negative
patientsremains undetermined.Bacterial vaginosis
was a possible cause in 23 of these women, based
on detection of clue cells by microscopy. An addi-
tional 4 women were positive for T. vaginalis by
microscopic examination. Other possible causes
of the observed symptoms, not evaluated in the
present study, include allergic vaginitis, papillo-
mavirus infection, desquamative vaginitis,
cervicitis or estrogen deficiency. In addition, we
acknowledge that in the Candida positive group,
clinical signs and symptoms in at least some of the
women may have been due to causes other than
the presence of Candida species. However, the
strong association between culture and wet mount
suggests the presence of a high Candida concentra-
tion in the majority of the positive women and,
therefore, an increased likelihood of Candida-
related symptomatology.
Host factors must also be taken into consider-
ation when attempting to diagnose vulvovaginitis.
It has been reported that there is no association
between the Candida concentration in the vagina
and clinical symptoms13. Women with Candida
counts as low as 100 organisms/ml may be highly
symptomatic while some women with vaginal
Candida concentrations as high as 10 000/ml may
be asymptomatic. Thus, women who are allergic
to Candida antigens or products14 can become
symptomatic even when vaginal concentrationsof
this organism are below the level detectable by
culture.Furthermore,a low level of Candida in the
vagina can synergize with histamine released in
response to otherallergens to induceprostaglandin
E2 production15. This, in turn, inhibits the cell-
mediated immune response necessary to prevent
Candida proliferation.
It is apparent that patient symptomatology,
clinical examination and medical history are
insufficient to distinguish vulvovaginitis associated
with thepresence ofa Candida species fromvulvo-
vaginitis due to other causes. Initiation of anti-
fungal treatment based solely on these criteria will
be ineffective for the many women who are nega-
tive for this microorganism. In symptomatic
women, a positive wet mount or culture for
Candida species is necessary to determine whether
this microbe is present.
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